Skip to content
StockMarketAgent
Direct answer
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Stock analysis

ZTS fair value $109–$170

By StockMarketAgent.AI team· supervised by
分析日: 2026-05-12次回更新: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
株価
$76.94
▲ +62.83 (+81.66%)
公正価値
$140
$109–$170
評価
強い買い
confidence 88/100
上昇余地
+81.7%
upside to fair value
安全余裕率
$118.80
MoS level · 15%
時価総額
$32.3B
P/E fwd 10.3
英語版にフォールバックJA
翻訳中のため英語版を表示しています
このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

§1 エグゼクティブサマリー

  • Composite fair value $140 with high case $170.
  • Implied upside of 81.7% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$76.94Price
Low $109.15
Mid $139.77
High $170.49

Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.

  • Intangible assets via unmatched patent
    Intangible assets via unmatched patent portfolio and brand loyalty.
  • High switching costs for veterinary
    High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
  • Cycle upside
    Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.

§2 ベアケース

A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCFReverse DCFInverts a standard DCF: instead of solving for fair value, we solve for the growth rate the current price already implies — a useful test of whether the market's assumptions are reasonable. implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. against such cyclical shocks.

このテーゼが崩れる経路

Margin Contraction

· Low

Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.

FV impact
Valuation compresses to the $109.15 low-end threshold.

Livestock Headwinds

· Medium

Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.

FV impact
Mild drag on terminal value generation and forward EPS.

Macro Demand Shock

· Medium

Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.

FV impact
Near-term EPS shock testing the $110 forward earnings scenario value.
監視すべき早期警戒シグナル
指標現在トリガーしきい値
Operating margin contracting below 35% over two consecutive quarters.MonitorDeterioration versus the report thesis
Forward EPS growth turning negative.MonitorDeterioration versus the report thesis
ROIC dropping precipitously toward the 8.43% WACC.MonitorDeterioration versus the report thesis
Erosion of the 71.8% gross margin floor.MonitorDeterioration versus the report thesis
Accelerated generic approvals targeting core parasiticide or dermatology portfolios.MonitorDeterioration versus the report thesis

§3 財務履歴

損益計算書 — 直近6期
項目T−0T−1T−2T−3CAGR
期間2022-12-312023-12-312024-12-312025-12-31Trend
売上高$8.08B$8.54B$9.26B$9.47B+5.4%
売上総利益$5.63B$5.98B$6.54B$6.80B+6.5%
営業利益$2.93B$3.07B$3.39B$3.60B+7.1%
純利益$2.11B$2.34B$2.49B$2.67B+8.1%
EPS (希薄化後)$4.49$5.07$5.47$6.02+10.3%
EBITDA$3.34B$3.67B$3.86B$4.07B+6.8%
研究開発$539.0M$614.0M$686.0M$698.0M+9.0%
販管費$2.01B$2.15B$2.32B$2.38B+5.8%

品質スコア

OCF / 純利益
1.09×
>1 は利益の質が高いことを示す
会計品質ゲート
Fail
セクター調整後ゲート
ROIC
22.5%
投下資本利益率
セクション 3

Numbers analysis

キャッシュフロー

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

資本配分

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

個人サブスクライバー — §4以降11セクション追加

完全な分析を読む — 11セクション追加。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

カバー対象の全ティッカーの完全なレポート
24か月分の評価アーカイブ
ウォッチリストブリーフィング + 評価変更アラート
任意の言語でのPDF + DOCXエクスポート
無料トライアルを開始
いつでもキャンセル可能。
REVERSE DCF FAQ

ZTS reverse dcf questions

  1. Reverse DCF for ZTS (ZTS) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.
FAQ

ZTS — frequently asked questions

  1. Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Related coverage

Names readers of ZTS also follow

Same archetype: mature-compounder